Listed

INVO Fertility, Inc.: Form 10-K/A for the period ended Dec 31, 2023

Filed with the SEC on Nov 19, 2024 and accepted by EDGAR at Nov 19, 2024, 16:05 ET.

Share

Controls and procedures

As filed, 6,355 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act, that are designed to be effective in providing reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to our management to allow timely decisions regarding required disclosure.

Our management, including the Chief Executive Officer and the Chief Financial Officer, carried out an evaluation of the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, as of the end of the period covered by this report. These disclosure controls and procedures are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were not effective as of December 31, 2023 due solely to the events that led to the restatements of our audited financial statements for the periods ending June 30, 2021 through June 30, 2024. As a result, management determined a material weakness in our internal control over financial reporting existed due to the accounting treatment of our right-of-use (“ROU”) asset and corresponding lease liability for our operating leases on our balance sheet. Management’s review was insufficient to identify an error in the incremental borrowing rate that led to our restatement of our financial statements, as described in Notes 2 and 3 to the Notes to Financial Statements included in this Form 10-K. In light of this material weakness, we performed additional analysis as deemed necessary to ensure that our financial statements were prepared in accordance with U.S. generally accepted accounting principles. Accordingly, management believes that the financial statements included in this Annual Report on Form 10-K present fairly in all material respects our financial position, results of operations and cash flows for the period presented.

Management’s Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting of the Company. Our management conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control—Integrated Framework (1992 Framework) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on the evaluation of our internal control over financial reporting, management has concluded that, as of December 31, 2023, our internal control over financial reporting was not effective due to material weaknesses related to (1) a limited segregation of duties due to our lack of formal control documentation, limited resources, and the small number of employees, and (2) a lack of adequate accounting resources to properly account for complex accounting transactions. Management has determined that these control deficiencies constitute material weaknesses, which could result in material misstatements of significant accounts and disclosures that could result in a material misstatement to our interim or annual financial statements that would not be prevented or detected.

This annual report does not include an attestation report of the company’s registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the company’s registered public accounting firm pursuant to rules of the SEC.

Limitations on Effectiveness of Controls and Procedures

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include, but are not limited to, the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control.

The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

Changes in Internal Control over Financial Reporting

There were no changes to our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2023-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue12 months2023-01-01 to 2023-12-31$3.0mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Research and development12 months2023-01-01 to 2023-12-31$165.9kus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative12 months2023-01-01 to 2023-12-31$7.5mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income12 months2023-01-01 to 2023-12-31−$6.8mus-gaap:OperatingIncomeLoss
Interest expense12 months2023-01-01 to 2023-12-31$925.9kus-gaap:InterestExpense
Income tax12 months2023-01-01 to 2023-12-31$27.8kus-gaap:IncomeTaxExpenseBenefit
Net income12 months2023-01-01 to 2023-12-31−$8.0mus-gaap:NetIncomeLoss
Diluted EPS12 months2023-01-01 to 2023-12-31−$5.13us-gaap:EarningsPerShareDiluted
Basic EPS12 months2023-01-01 to 2023-12-31−$5.13us-gaap:EarningsPerShareBasic
Diluted shares (weighted)12 months2023-01-01 to 2023-12-311,565,951 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow12 months2023-01-01 to 2023-12-31−$4.8mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure12 months2023-01-01 to 2023-12-31$444.7kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2023-12-31$232.4kus-gaap:Cash
Current assetsAt period end2023-12-31$1.3mus-gaap:AssetsCurrent
Total assetsAt period end2023-12-31$18.5mus-gaap:Assets
Current liabilitiesAt period end2023-12-31$8.0mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2023-12-31$17.6mus-gaap:Liabilities
Shareholders' equityAt period end2023-12-31$892.8kus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001493152-24-046808. Last ingested by Listed: Nov 4, 2026, 19:16 ET. Listed shows no prices and gives no investment advice.